Lymphoma African

African lymphoma, or Burkitt's lymphoma, is a form of non-Hodgkin's lymphoma that develops in preschool children and adolescents. In adulthood, this lymphoma is rare.

Cancer grows in lymph nodes of different sizes - from millimeter to giant. At an early stage, the tumor is usually invisible; it is noticed when it grows so much that it can be felt. Early consultation with a doctor allows you to start treatment on time and increase the chances of recovery. According to statistics, the disease affects boys more often, and lymphoma is widespread mainly in hot African countries - Rwanda, Uganda and Burundi. Although the future prognosis of the disease is more favorable, it is still considered one of the most malignant childhood cancers. The average age of a patient at the time of diagnosis of Burkitt's lymphoma is 9 years, girls get sick much less often. The peak occurs when children are three years old. Predisposition to the disease depends on a person’s genotype; those who inherit two mutations from their parents are more likely to get sick. The spread of the disease is associated with the fact that many people live in these regions, including children, who became infected with monkeypox on the last continent of the Earth - Africa. Of the immune cells of the varicella-zoster virus, humans suffer from one type of monkeypox virus - the herpes virus. Perhaps it is the heredity of that genotype, the tendency in a person to form one type of virus out of two, that is the cause of this disease.

Berkita's lymphoma can be found in the lymph node, where the infection multiplies very actively. Immune system cells that fight infection also multiply there. Over time, this process leads to tumors growing very quickly and metastases developing. And at different stages of this cancer process we are talking about oncology of varying degrees of neglect, which prognostically looks dangerous.

Treatment of Burkitts lymphoma for children can be carried out using different methods - chemotherapy, radiation and surgery. Patients also benefit from immunotherapy medications that stimulate the immune system to fight the disease. Unfortunately, most patients relapse and often do not fully recover, meaning secondary lesions will continue to be affected. Recovery statistics in rare cases are only 20-30%.